Review of recent clinical trials of Hospital-acquired pneumonia and ventilator-associated pneumonia: A perspective from Academia

Clinical Infectious Diseases

Volumn 51, Issue SUPPL. 1, 2010, Pages

  Kollef, Marin H ^a  

^a BARNES JEWISH HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CEFTAZIDIME; CEFTOBIPROLE; LINEZOLID; VANCOMYCIN; ANTIINFECTIVE AGENT;

BACTERIAL PNEUMONIA; CLINICAL TRIAL; CONFERENCE PAPER; DIAGNOSTIC ERROR; DRUG EFFECT; HOSIPITAL ACQUIRED PNEUMONIA; HOSPITAL ACQUIRED PNEUMONIA; HOSPITAL ASSOCIATED PNEUMONIA; HOSPITAL INFECTION; HUMAN; INFORMED CONSENT; LOWER RESPIRATORY TRACT INFECTION; MEDICAL PRACTICE; PATHOGENESIS; PRIORITY JOURNAL; VENTILATOR ASSOCIATED PNEUMONIA; CLINICAL TRIAL (TOPIC); CROSS INFECTION; HOSPITAL; METHODOLOGY; MICROBIOLOGY; PATIENT SELECTION; PNEUMONIA, BACTERIAL; PNEUMONIA, VENTILATOR-ASSOCIATED; TREATMENT OUTCOME;

ANTI-BACTERIAL AGENTS; CLINICAL TRIALS AS TOPIC; CROSS INFECTION; HOSPITALS; HUMANS; PATIENT SELECTION; PNEUMONIA, BACTERIAL; PNEUMONIA, VENTILATOR-ASSOCIATED; RESEARCH DESIGN; TREATMENT OUTCOME;

EID: 77955668349     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/653037     Document Type: Conference Paper

References (43)

1. American Thoracic Society, Infectious Diseases Society of America. Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. Am J Respir Crit Care Med 2005; 171:388-416.
2. Anand N, Kollef MH. The alphabet soup of pneumonia: CAP, HAP, HCAP, NHAP, and VAP. Semin Respir Crit Care Med 2009; 30:3-9.
3. Craven DE. What is healthcare-associated pneumonia, and how should it be treated? Curr Opin Infect Dis 2006; 19:153-160.
4. Arias CA, Murray BE. Antibiotic-resistant bugs in the 21st century-a clinical super-challenge. N Engl J Med 2009; 360:439-443.
5. Kollef MH, Napolitano LM, Solomkin JS, et al. Health care-associated infection (HAI): a critical appraisal of the emerging threat-proceedings of the HAI Summit. Clin Infect Dis 2008; 47(suppl 1):S55-S99.
6. Maffessanti M, Berlot G, Bortolotto P. Chest roentgenology in the intensive care unit: an overview. Eur Radiol 1998; 8:69-78.
7. Chastre J, Fagon JY. Ventilator-associated pneumonia. Am J Resp Crit Care Med 2002; 165:867-903.
8. Klompas M. Does this patient have ventilator-associated pneumonia? JAMA 2007; 297:1583-1593.
9. Kollef MH, Morrow LE, Niederman MS, et al. Clinical characteristics and treatment patterns among patients with ventilator-associated pneumonia. Chest 2006; 129:1210-1218.
10. Fagon J, Patrick H, Haas DW, et al. Treatment of gram-positive nos-ocomial pneumonia: prospective randomized comparison of quinu-pristin/ dalfopristin versus vancomycin. Nosocomial Pneumonia Group. Am J Respir Crit Care Med 2000; 161:753-762.
11. Kollef MH, Afessa B, Anzueto A, et al. Silver-coated endotracheal tubes and incidence of ventilator-associated pneumonia: the NASCENT randomized trial. JAMA 2008; 300:805-813.
12. Kollef M, Pittet D, Sánchez García M, et al. A randomized double-blind trial of iseganan in prevention of ventilator-associated pneumonia. Am J Respir Crit Care Med 2006; 173:91-97.
13. Canadian Critical Care Trials Group. A randomized trial of diagnostic techniques for suspected ventilator-associated pneumonia. N Engl J Med 2006; 355:2619-2630.
14. Heyland DK, Dodek P, Muscedere J, Day A, Cook D. Canadian Critical Care Trials Group. Randomized trial of combination versus mono-therapy for the empiric treatment of suspected ventilator-associated pneumonia. Crit Care Med 2008; 36:737-744.
15. Beardsley JR, Williamson JC, Johnson JW, Ohl CA, Karchmer TB, Bowton DL. Using local microbiologic data to develop institution-specific guidelines for the treatment of hospital-acquired pneumonia. Chest 2006; 130:787-793.
16. Noel GJ, Strauss RS, Amsler K, Heep M, Pypstra R, Solomkin JS. Results of a double-blind, randomized trial of ceftobiprole treatment of complicated skin and skin structure infections caused by gram-positive bacteria. Antimicrob Agents Chemother 2008; 52:37-44.
17. Noel GJ, Bush K, Bagchi P, Ianus J, Strauss RS. A randomized, double-blind trial comparing ceftobiprole medocaril with vancomycin plus ceftazidime for the treatment of patients with complicated skin and skin structure infections. Clin Infect Dis 2008; 46:647-655.
18. Noel GJ, Strauss RS, Shah A, Bagchi P. Ceftobiprole versus ceftazidime combined with linezolid for treatment of patients with nosocomial pneumonia. In: Program and abstracts of the 48th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC: 2008. Abstract K-486.
19. Drugs.com. Tygacil. http://www.drugs.com/pro/tygacil.html. Accessed 24 February 2009.
20. Rubenfeld GD. Improving clinical trials of long-term outcomes. Crit Care Med 2009; 37:S112-S116.
21. Harvey SE, Elbourne D, Ashcroft J, Jones CM, Rowan K. Informed consent in clinical trials in critical care: Experience from the PAC-Man Study. Intensive Care Med 2006; 32:2020-2025.
22. Rello J, Kollef M, Diaz E, et al. Reduced burden of bacterial airway colonization with a novel silver-coated endotracheal tube in a randomized multiple-center feasibility study. Crit Care Med 2006; 34: 2766-2772.
23. Fan E, Shahid S, Kondreddi VP, et al. Informed consent in the critically ill: a two-step approach incorporating delirium screening. Crit Care Med 2008; 36:94-99.
24. Gaynes R, Edwards JR. Overview of nosocomial infections caused by gram-negative bacilli. Clin Infect Dis 2005; 41:848-854.
25. Kollef MH, Shorr A, Tabak YP, Gupta V, Liu LZ, Johannes RS. Epidemiology and outcomes of healthcare-associated pneumonia: results from a large US database of culture-positive pneumonia. Chest 2005; 128:3854-3862.
26. Boucher HW, Talbot GH, Bradley JS, et al. Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America. Clin Infect Dis 2009; 48:1-12.
27. Shorr AF, Susla GB, Kollef MH. Quinolones for treatment of noso-comial pneumonia: a meta-analysis. Clin Infect Dis 2005; 40: S115-S122.
28. West M, Boulanger BR, Fogarty C, et al. Levofloxacin compared with imipenem/cilastatin followed by ciprofloxacin in adult patients with nosocomial pneumonia: a multicenter, prospective, randomized, open-label study. Clin Ther 2003; 25:485-506.
29. Kuti JL, Maglio D, Nightingale CH, Nicolau DP. Economic benefit of a meropenem dosage strategy based on pharmacodynamic concepts. Am J Health Syst Pharm 2003; 60:565-568.
30. Santos Filho L, Eagye KJ, Kuti JL, Nicolau DP. Addressing resistance evolution in Pseudomonas aeruginosa using pharmacodynamic modelling: application to meropenem dosage and combination therapy. Clin Microbiol Infect 2007; 13:579-585.
31. Kollef MH, Ward S. The influence of mini-BAL cultures on patient outcomes: implications for the antibiotic management of ventilator-associated pneumonia. Chest 1998; 113:412-420.
32. Ibrahim EH, Sherman G, Ward S, Fraser VJ, Kollef MH. The influence of inadequate antimicrobial treatment of bloodstream infections on patient outcomes in the ICU setting. Chest 2000; 118:146-155.
33. Wilcox MH, Tack KJ, Bouza E, et al. Complicated skin and skin-structure infections and catheter-related bloodstream infections: non-inferiority of linezolid in a phase 3 study. Clin Infect Dis 2009; 48: 203-212.
34. Senior K. FDA issues linezolid warning. Lancet Infect Dis 2007; 7(5): 310.
35. Chastre J, Wunderink R, Prokocimer P, et al. Efficacy and safety of intravenous infusion of doripenem versus imipenem in ventilator-associated pneumonia: a multicenter, randomized study. Crit Care Med 2008; 36:1089-1096.
36. Rea-Neto A, Niederman M, Lobo SM, et al. Efficacy and safety of doripenem versus piperacillin/tazobactam in nosocomial pneumonia: a randomized, open-label, multicenter study. Curr Med Res Opin 2008; 24:2113-2126.
37. Falagas ME, Siempos II, Vardakas KZ. Linezolid versus glycopeptide or beta-lactam for treatment of Gram-positive bacterial infections: meta-analysis of randomised controlled trials. Lancet Infect Dis 2008;8: 53-66.
38. Wunderink RG, Rello J, Cammarata SK, Croos-Dabrera RV, Kollef MH. Linezolid vs vancomycin: analysis of two double-blind studies of patients with methicillin-resistant Staphylococcus aureus nosocomial pneumonia. Chest 2003; 124:1789-1797.
39. Edwards SJ, Emmas CE, Campbell HE. Systematic review comparing meropenem with imipenem plus cilastatin in the treatment of severe infections. Curr Med Res Opin 2005; 21:785-794.
40. Regulatory watch: non-inferiority-trial discussions impact new drug applications. Nat Rev Drug Discov 2009; 8:10.
41. Fleming TR. Powers JH. Issues in noninferiority trials: the evidence in community-acquired pneumonia. Clin Infect Dis 2008; 47(suppl 3): S108-S120.
42. Schuetz P, Christ-Crain M, Thomann R, et al. Effect of procalcitonin-based guidelines vs standard guidelines on antibiotic use in lower respiratory tract infections: the ProHOSP randomized controlled trial. JAMA 2009; 302:1059-1066.
43. Bouadma L, Luyt CE, Tubach F, et al. Use of procalcitonin to reduce ICU patients' exposure to antibiotics-the randomized controlled PRORATA trial. Lancet 2010; 375(9713):463-474.